Denise Gavin, PhD

Center for Biologics Evaluation and Research – Food and Drug Administration · company speakers →

Dr. Gavin will outline the regulatory considerations for when a genome engineering trial is reviewed by the FDA.

Is this you? Claim this profile →

No public contact links on file.

Speaking history

ASH Meeting on Hematologic Malignancies

21 August 2026 Chicago, United States “Regulatory Considerations for Gene Therapy Products involving Gene Editing Technologies”

Sourcing speakers for your event?

Browse the speaker directory →